vTv Therapeutics Inc - Ordinary Shares - Class A
VTVT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$257.05M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $257.05 Million |
|---|---|
| Enterprise Value | $179.89 Million |
| Earnings per Share | $-3.2 |
| Beta | 0.26 |
| Outstanding Shares | 12,423,917 |
Return
| Return on Equity | -11.02% |
|---|---|
| Return on Assets | -9.77% |
| Return on Invested Capital | 2.75% |
Valuation & Multiples
| P/E Ratio | 701 |
|---|---|
| PEG | 2086.69 |
| Price to Sales | 10.35 |
| Price to Book Ratio | 4.14 |
| Enterprise Value to Revenue | 4.89 |
| Enterprise Value to EBIT | 91.55 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS
-$0.94
Est. -$1.09Revenue Estimate
$333,330
Consensus analyst estimateNext Earnings Call
Expected Date
March 9, 2027
EPS Estimate
-$2.39
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.27%▼ 12.68% |
|---|---|
| Total Invested | $1.04M▼ 98.28% |
| Investors Holding | 6▼ 38.00% |
About vTv Therapeutics Inc
25 employees
CEO: Stephen Holcombe
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and infla...